LaSalle Street Capital Management’s Emergent Biosolutions EBS Stock Holding History

LaSalle Street Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-16,342	Closed	-$594K	–	92
2016 Q1	$594K	Sell	16,342 -337	-2%	-$11.9K	0.58%	53
2015 Q4	$667K	Buy	16,679 +782	+5%	+$27.3K	0.66%	49
2015 Q3	$453K	Hold	15,897	–	–	0.48%	58
2015 Q2	$524K	Hold	15,897	–	–	0.51%	57
2015 Q1	$457K	Sell	15,897 -3,433	-18%	-$98.5K	0.45%	61
2014 Q4	$526K	Buy	+19,330	New	+$461K	0.51%	57

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LaSalle Street Capital Management's EBS Position: Q2 2016 in Review

LaSalle Street Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2016, closing a stake of 16,342 shares — an estimated $594K sold.

LaSalle Street Capital Management first reported a position in EBS in Q4 2014 and held it in 6 quarters. The position peaked at $667K in Q4 2015. 225 funds tracked by Wall St. Rank hold EBS as of Q2 2016.

LaSalle Street Capital Management reported no remaining Emergent Biosolutions position as of Q2 2016 after selling out during the quarter.
LaSalle Street Capital Management sold 16,342 Emergent Biosolutions shares in Q2 2016, an estimated $594K.
LaSalle Street Capital Management first reported a position in Emergent Biosolutions in Q4 2014 and held it in 6 quarters.
LaSalle Street Capital Management's Emergent Biosolutions position peaked at $667K in Q4 2015.
225 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2016.

Based on LaSalle Street Capital Management's 13F filing for Q2 2016, filed 19 Jul 2016.